About UCSF Search UCSF UCSF Medical Center

Emily K. Bergsland, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
bergsland_emily

Professor of Clinical Medicine, UCSF
Ernest Rosenbaum, MD, Endowed Chair in Medical Oncology, UCSF

Phone: (415) 353-9888 (appts)
Box 1705, UCSF
San Francisco, CA 94143-1702

View on UCSF Profiles


Additional Websites


Education

University of Wisconsin, B.S., 1985, Biochemistry and Molecular Biology
University of Minnesota, M.D., 1982
 


Professional Experience

  • 1989-92
    Intern, Dept. of Medicine, University of California San Francisco
  • 1990-92
    Resident, Dept. of Medicine, University of California San Francisco
  • 1992-92
    Chief Resident and Assistant Chief of the Medical Service, Dept. of Medicine, University of California San Francisco
  • 1993-92
    Fellow, Medical Oncology, University of California San Francisco
  • 1994-1992
    Research Fellow (P I: Douglas Hanahan, Ph.D.), Department of Biochemistry and Biophysics, University of California San Francisco
  • Transgenic mouse models of tumorigenesis
  • 1996-1992
    Clinical Instructor, Dept. of Medicine (Division of Hematology/Oncology), UCSF
  • 1998-2002
    Assistant Clinical Professor, Dept of Medicine (Division of Hematology/Oncology), UCSF
  • 2003-2002
    Associate Director, Hematology/Oncology Fellowship Program, UCSF
  • 2004-present
    Associate Professor, Dept. of Medicine, Division of Hematology/Oncology, UCSF
  • 2006-present
    Director of Education and Fellowship Program Director, Hematology/Oncology

Honors & Awards

  • 1982
    Phi Beta Kappa
  • 1985-82
    Vine Scholarship, University of Minnesota
  • 1982
    May Sine Peterson Award, University of Minnesota
  • 1982
    Alpha Omega Alpha
  • 1995-92
    Molecular Medicine Fellowship, University of California San Francisco

Selected Publications

  1. Affara NI, Ruffell B, Medler TR, Gunderson AJ, Johansson M, Bornstein S, Bergsland E, Steinhoff M, Li Y, Gong Q, Ma Y, Wiesen JF, Wong MH, Kulesz-Martin M, Irving B, Coussens LM. B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. Cancer Cell. 2014 Jun 16; 25(6):809-21.
    View on PubMed
  2. Fidelman N, Kerlan RK, Hawkins RA, Taylor AG, Kohi MP, Kolli KP, Bergsland EK, Kelley RK, Ko AH, Korn WM, McWhirter RM, Luan J, Venook AP. (90)Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study. J Gastrointest Cancer. 2014 Jun; 45(2):168-80.
    View on PubMed
  3. Becerra CR, Salazar R, Garcia-Carbonero R, Thomas AL, Vázquez-Mazón FJ, Cassidy J, Maughan T, Castillo MG, Iveson T, Yin D, Green S, Bergsland EK. Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial. Cancer Chemother Pharmacol. 2014 Apr; 73(4):695-702.
    View on PubMed
  4. Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer. 2013 Oct 1; 109(7):1725-34.
    View on PubMed
  5. Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene. 2014 Mar 20; 33(12):1590-600.
    View on PubMed
  6. Kelley RK, Nimeiri HS, Munster PN, Vergo MT, Huang Y, Li CM, Hwang J, Mulcahy MF, Yeh BM, Kuhn P, Luttgen MS, Grabowsky JA, Stucky-Marshall L, Korn WM, Ko AH, Bergsland EK, Benson AB, Venook AP. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. Ann Oncol. 2013 Jul; 24(7):1900-7.
    View on PubMed
  7. Bergsland EK. Introduction: recent advances in the genetics, diagnosis, and treatment of neuroendocrine tumors. Semin Oncol. 2013 Feb; 40(1):1-3.
    View on PubMed
  8. Bergsland EK. The evolving landscape of neuroendocrine tumors. Semin Oncol. 2013 Feb; 40(1):4-22.
    View on PubMed
  9. Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. Am J Clin Oncol. 2012 Oct; 35(5):411-7.
    View on PubMed
  10. Parekh JR, Wang SC, Bergsland EK, Venook AP, Warren RS, Kim GE, Nakakura EK. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients. Pancreas. 2012 Aug; 41(6):840-4.
    View on PubMed
  11. Kulke MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Choti MA, Clark OH, Doherty GM, Eason J, Emerson L, Engstrom PF, Goldner WS, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Moley JF, Pillarisetty VG, Saltz L, Schteingart DE, Shah MH, Shibata S, Strosberg JR, Vauthey JN, White R, Yao JC, Freedman-Cass DA, Dwyer MA. Neuroendocrine tumors. J Natl Compr Canc Netw. 2012 Jun 1; 10(6):724-64.
    View on PubMed
  12. Paulson AS, Bergsland EK. Systemic therapy for advanced carcinoid tumors: where do we go from here? J Natl Compr Canc Netw. 2012 Jun 1; 10(6):785-93.
    View on PubMed
  13. Atreya CE, Ducker GS, Feldman ME, Bergsland EK, Warren RS, Shokat KM. Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer. Invest New Drugs. 2012 Dec; 30(6):2219-25.
    View on PubMed
  14. Garcia-Aguilar J, Smith DD, Avila K, Bergsland EK, Chu P, Krieg RM. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg. 2011 Jul; 254(1):97-102.
    View on PubMed
  15. Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol. 2011 Mar 1; 29(7):934-43.
    View on PubMed
  16. Wang YC, Iezza G, Zuraek MB, Jablons DM, Theodore PR, Bergsland EK, Donner DB, Warren RS, Nakakura EK. Lack of NKX2.2 expression in bronchopulmonary typical carcinoid tumors: implications for patients with neuroendocrine tumor metastases and unknown primary site. J Surg Res. 2010 Sep; 163(1):47-51.
    View on PubMed
  17. Wang SC, Parekh JR, Zuraek MB, Venook AP, Bergsland EK, Warren RS, Nakakura EK. Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg. 2010 Mar; 145(3):276-80.
    View on PubMed
  18. Wang YC, Zuraek MB, Kosaka Y, Ota Y, German MS, Deneris ES, Bergsland EK, Donner DB, Warren RS, Nakakura EK. The ETS oncogene family transcription factor FEV identifies serotonin-producing cells in normal and neoplastic small intestine. Endocr Relat Cancer. 2010 Mar; 17(1):283-91.
    View on PubMed
  19. Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1051-7.
    View on PubMed
  20. Kulke MH, Bergsland EK, Yao JC. Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med. 2009 Jan 8; 360(2):195-7.
    View on PubMed

Go to UCSF Profiles, powered by CTSI